US Bancorp’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

US Bancorp’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-517	Closed	-$21.1K	–	4223
2024 Q2	$21.1K	Hold	517	–	–	﹤0.01%	3046
2024 Q1	$21.9K	Hold	517	–	–	﹤0.01%	3054
2023 Q4	$21.9K	Buy	517 +360	+229%	+$10.3K	﹤0.01%	3016
2023 Q3	$3.43K	Buy	+157	New	+$3.93K	﹤0.01%	3539
2023 Q1	–	Sell	-55	Closed	-$1.74K	–	4221
2022 Q4	$1.74K	Buy	+55	New	+$1.55K	﹤0.01%	3811

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

US Bancorp's CERE Position: Q3 2024 in Review

US Bancorp sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 517 shares — an estimated $21.1K sold.

US Bancorp first reported a position in CERE in Q4 2022 and held it in 5 quarters. The position peaked at $21.9K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

US Bancorp reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
US Bancorp sold 517 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $21.1K.
US Bancorp first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 5 quarters.
US Bancorp's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $21.9K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on US Bancorp's 13F filing for Q3 2024, filed 28 Oct 2024.